BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 12771913)

  • 1. Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity.
    Cianci G; Morelli MF; Cannita K; Morese R; Ricevuto E; Di Rocco ZC; Porzio G; Lanfiuti Baldi P; Ficorella C
    Br J Cancer; 2003 May; 88(10):1507-9. PubMed ID: 12771913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute heart failure after treatment with 5-fluorouracil.
    Georgieva S; Kinova E; Iordanov V; Gudev A; Tzekova V; Velikova M
    J BUON; 2007; 12(1):113-6. PubMed ID: 17436411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy -- a survey of 427 patients.
    Tsavaris N; Kosmas C; Vadiaka M; Efremidis M; Zinelis A; Beldecos D; Sakelariou D; Koufos C; Stamatelos G
    Med Sci Monit; 2002 Jun; 8(6):PI51-7. PubMed ID: 12070449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symptomatic cardiotoxicity associated with 5-fluorouracil.
    Meyer CC; Calis KA; Burke LB; Walawander CA; Grasela TH
    Pharmacotherapy; 1997; 17(4):729-36. PubMed ID: 9250550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Angina attack caused by 5-fluorouracil infusion--report of a case and review of the literature].
    Yokoyama T; Hosoya Y; Aoki T; Saito S; Nihei Y; Kobayashi N; Shoji M; Saito Y; Nagai H
    Gan To Kagaku Ryoho; 2002 Oct; 29(10):1805-8. PubMed ID: 12402434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine.
    Jensen SA; Sørensen JB
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):487-93. PubMed ID: 16418875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoropyrimidine-associated cardiotoxicity: revisited.
    Saif MW; Shah MM; Shah AR
    Expert Opin Drug Saf; 2009 Mar; 8(2):191-202. PubMed ID: 19309247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma.
    Keene KS; Rich TA; Penberthy DR; Shepard RC; Adams R; Jones RS
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):97-103. PubMed ID: 15850908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
    Ychou M; Duffour J; Kramar A; Debrigode C; Gourgou S; Bressolle F; Pinguet F
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):282-90. PubMed ID: 12827293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bolus 5-Fluorouracil as an alternative modality to infusion 5-Fluorouracil in a patient with rectal cancer and capecitabine-induced cardiotoxicity.
    Shaib W; Lee V; Saif MW
    In Vivo; 2009; 23(5):821-6. PubMed ID: 19779118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repetitive chemoembolization with melphalan plus intra-arterial immuno-chemotherapy within 5-fluorouracil and granulocyte-macrophage colony-stimulating factor (GM-CSF) as effective first- and second-line treatment of disseminated colorectal liver metastases.
    Müller H; Nakchbandi V; Chatzisavvidis I; von Voigt C
    Hepatogastroenterology; 2003; 50(54):1919-26. PubMed ID: 14696433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [5-fluorouracil: cause of a fatal myocardial infarction in combined radiochemotherapy?].
    Maurer U; Härle M; Jungius KP
    Strahlenther Onkol; 1996 May; 172(5):257-9. PubMed ID: 8633257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon.
    Czito BG; Hong TJ; Cohen DP; Tyler DS; Lee CG; Anscher MS; Ludwig KA; Seigler HF; Mantyh C; Morse MA; Lockhart AC; Petros WP; Honeycutt W; Spector NL; Ertel PJ; Mangum SG; Hurwitz HI
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):779-85. PubMed ID: 14967434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Coronary artery stenting in the treatment of 5-fluorouracil-induced unstable angina].
    Grześk G; Orzałkiewicz Z; Polak G; Przybył R; Nartowicz E; Szadujkis-Szadurski L; Grabczewska Z
    Przegl Lek; 2003; 60(1):46-8. PubMed ID: 12884648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cardiotoxicity of 5-fluorouracil].
    Pan L; Yang X; Song H
    Zhonghua Fu Chan Ke Za Zhi; 1996 Feb; 31(2):86-9. PubMed ID: 8758800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease.
    Tsibiribi P; Descotes J; Lombard-Bohas C; Barel C; Bui-Xuan B; Belkhiria M; Tabib A; Timour Q
    Bull Cancer; 2006 Mar; 93(3):E27-30. PubMed ID: 16567310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
    Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial.
    Hamaguchi T; Shirao K; Yamamichi N; Hyodo I; Koizumi W; Seki S; Imamura T; Honma H; Ohtsu A; Boku N; Mukai T; Yamamoto S; Fukuda H; Yoshida S;
    Jpn J Clin Oncol; 2008 Jun; 38(6):432-7. PubMed ID: 18515821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.